Ready 8-Ks
3
Latest filing
August 3, 2026, 7:03 AM ET
Top materiality
0.80
Event mix
earnings ×2 · other_material ×1
Sentiment
2 pos · 0 neg · 1 neu
Recent 8-K filings for SPTX
Highest-materiality recent filing
Seaport Therapeutics adopts new charter authorizing 700M shares, completes IPO
- Filed amended charter authorizing 700M total shares: 500M voting common, 200M non-voting common, 10M undesignated preferred.
- Eliminated references to prior preferred stock series; Board may issue undesignated preferred in series.
-
Seaport Therapeutics Q2 net loss $62.6M; cash $427.3M; GlyphAllo Phase 2b on track for 1H 2027
Net loss of $62.6M for Q2 2026 vs $15.1M in Q2 2025; increase driven by one-time IPO-related stock-based compensation.
-
Seaport Q1 net loss $25.4M; cash $212.6M; GlyphAgo Ph1 shows liver safety; GlyphAllo Ph2b on track
Net loss $25.4M (vs $13.1M YoY); R&D expenses $21.4M, up from $10.5M YoY.
-
Seaport Therapeutics adopts new charter authorizing 700M shares, completes IPO
Filed amended charter authorizing 700M total shares: 500M voting common, 200M non-voting common, 10M undesignated preferred.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.70 · Most common event earnings